Mobile linear accelerator IORT systems — the self-shielded, transportable electron beam units delivering single-fraction radiation directly to the tumor bed during surgery without requiring dedicated shielded bunkers representing the fastest-growing technology segment — create the most access-expanding market opportunity, with the Intraoperative Radiation Therapy Market reflecting mobile LINAC as the democratization commercial driver.

IORT clinical rationale — the delivery of a concentrated radiation dose to the tumor bed immediately after surgical resection when microscopic residual disease is most vulnerable and oxygenation is optimal, eliminating the geometric miss risk of postoperative external beam radiation creating the therapeutic advantage. IORT reducing local recurrence rates by approximately forty to sixty percent in selected breast cancer, retroperitoneal sarcoma, and pancreatic cancer compared to surgery alone or surgery plus adjuvant EBRT.

Mobile LINAC vs. dedicated facility — the Mobetron (IntraOp), Liac (Sordina), and Novac7 (Ariane) mobile systems enabling IORT in standard operating rooms versus the intraoperative radiotherapy requiring radiation-shielded operating suites or transfer to radiotherapy departments creating the infrastructure flexibility. Mobile LINAC systems achieving approximately six to twelve MeV electron energies with self-shielded design reducing room modification costs from approximately one to two million dollars to two hundred to five hundred thousand dollars.

Breast cancer IORT adoption — the TARGIT-A and ELIOT trials demonstrating non-inferiority of single-fraction IORT to whole-breast external beam radiation for selected early-stage breast cancer creating the alternative to six-week EBRT courses. IORT for breast cancer capturing approximately fifty to fifty-five percent of the IORT market, with patient preference for single-treatment convenience driving adoption in appropriately selected low-risk patients.

Do you think mobile LINAC IORT will eventually replace conventional postoperative EBRT for all localized cancers amenable to IORT, or will the need for long-term follow-up data, patient selection criteria, and multidisciplinary coordination limit IORT to specialized centers and selected indications?

What are the leading mobile IORT systems and their clinical applications? Mobetron (IntraOp Medical): 6-12 MeV electrons; self-shielded; 50+ installations globally; breast, sarcoma, pancreatic, colorectal, head/neck; Liac (Sordina IORT Systems): 3-10 MeV; mobile; European leader; 100+ systems; Novac7 (Ariane Medical): 7-11 MeV; compact; emerging; Zeiss INTRABEAM: 50 kV X-rays (not LINAC); breast IORT; 500+ systems; Intrabeam different: Low-energy X-rays (50 kV); spherical applicators; 20 Gy at surface; rapid falloff; breast only; Applications: Breast (50-55% of IORT): early-stage, low-risk, elderly; Sarcoma (15-20%): retroperitoneal, extremity; Pancreatic (10-15%): locally advanced; Colorectal (10%): recurrent; Head/neck (5-10%): recurrent; Gynecologic (5%): recurrent cervical; Dose: 10-20 Gy single fraction (electrons); 20 Gy (INTRABEAM); Cost: Mobile LINAC — $1.5-3M; INTRABEAM — $500K-750K; Shielding — $200K-500K (mobile); $1-2M (dedicated); Reimbursement: CPT 77424 (IORT delivery); $3,000-8,000 per procedure; bundled in global surgical payment in some settings.

How does mobile IORT compare to conventional postoperative radiation therapy? Treatment course: IORT — single fraction (30-60 min during surgery); EBRT — 25-30 fractions over 5-6 weeks; Local control: Breast (selected) — equivalent to EBRT; Sarcoma — 40-60% recurrence reduction; Pancreatic — modest benefit (controversial); Toxicity: IORT — wound complications (10-15%), neuropathy (dose-dependent); EBRT — fatigue, skin reaction, cardiac (breast), lymphedema; Patient preference: IORT — 90%+ prefer single treatment; EBRT — adherence 80-85%; Cost: IORT — $3,000-8,000 (single); EBRT — $15,000-40,000 (course); Infrastructure: IORT — mobile system in OR; EBRT — dedicated linear accelerator bunker; Coordination: IORT — requires radiation oncologist in OR; EBRT — standard workflow; Market: IORT — $200-300M; 8-10% CAGR; mobile LINAC — 40% of market; 12-15% CAGR.

#IntraoperativeRadiationTherapy #IORT #MobileLINAC #BreastCancer #RadiationOncology #SurgicalOncology